2022 年 48 巻 11 号 p. 500-506
Cancer genome medicine is personalized medicine based on genetic information through cancer gene panel testing, in which cancer tissue and blood are analyzed by next-generation sequencers. Pharmacists participate in the expert committee in cancer gene medicine at Hiroshima University Hospital and provide clinical trial information based on the genetic mutation of each case. We have established a new database (Hirodai-DB) to improve the efficiency of providing clinical trial information and to increase the amount of clinical trial information provided. Six out of 123 cases actually proceeded to clinical trials using Hirodai-DB, and 2 out of 6 cases (33%) that proceeded to clinical trials used Hirodai-DB that was the only source of information. The establishment of the Hirodai-DB was considered to be useful for cancer genome medicine at this hospital.